Business analysis and market potential of drug screening technology for preventive and personalized therapy

Volchek I, Cotter P, Petrov A, Moore M
The EPMA journal · 2014 · doi:10.1186/1878-5085-5-s1-a105 · PMC4125952
OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-25 ⓘ

This business analysis evaluates the US market potential of a drug screening technology for preventive and personalized therapy, estimating significant cost savings for infectious diseases and cancer while identifying endometriosis as a prospective therapeutic application.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-25 · read from full text ⓘ

This paper conducts a business analysis to evaluate the US market potential of a novel drug screening technology designed for preventive and personalized therapy. The authors assess the economic impact of this method across several diseases, including hepatitis C, melanoma, HIV, and influenza, projecting significant cost savings for Medicare and Medicaid through increased treatment efficacy and reduced hospital stays. Additionally, the study highlights how targeted therapies could lower metastatic rates in cancer and decrease relapse frequencies in chronic infections like HPV and herpes. Relevance to endometriosis: listed as one perspective direction for the proposed preventive therapy method, though the paper's main focus is on infectious diseases and cancer.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,983 characters · extracted from pmc-nxml · 1 sections · click to expand

Section

We have taken the business analysis to evaluate US market potential of new technology for preventive and personalized therapy (PT) of human diseases – Method for screening drug preparations (Method) [ 1 ] and it impact on the public health. Six sexually transmitted diseases (HCV, HBV, HPV, HSV, HIV and genital chlamidiosis), influenza, other acute respiratory diseases (ARD) and cancer [ 2 ] were used for the analysis. PT can allow to save up to $17.5 – 19.25 billion for Medicare/Medicaid for US hepatitis C market. The cost of the treatment of one patient with melanoma stage II - III can decrease 3-fold (saved $3,950 per patient per year) while the efficacy have to increase 2 – 3-fold. At cancer forms with no effective and safe adjuvant therapy PT can decrease the rate of metastatic stage which requires high-cost cytostatic therapy. PT with antiretrovirals and cytostatics can allow reduction of high expense of hospital stay for the patients with AIDS and metastatic cancer due to higher efficacy. PT will decrease the rate of non-effective treatment and number of relapses of HPV-infection, genital herpes and urogenital chlamidyosis as well as the number of new cases due to less spreading via sexual contacts. Preventive PT of HPV-infection with unfavorable HPV types will lead to less number of cases with cervical neoplasia. Preventive PT in risk group of 1% cases of influenza (950,000 cases) will give the ability for the insurance companies to save money for the treatment of 2.8 – 3.4 mln episodes of influenza and ARD. At the same time the number of restricted-activity days will decrease for 10 – 12 mln, bed days – for 5 – 7 mln and work-loss days due to flu and other ARD – for 2 – 2.5 mln. The Market potential data of Method are summarized in the table below. Other perspective directions of PT using proposed Method: atherosclerosis, diabetes, endometriosis, chronic fatigue syndrome; CMV-, EBV-, Helicobacter Pylori infections, sepsis and tuberculosis.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-23T09:30:01.253652+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC